Trials / Completed
CompletedNCT02268786
Single Embryo TrAnsfeR of Euploid Embryo
Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 661 (actual)
- Sponsor
- Illumina, Inc. · Industry
- Sex
- Female
- Age
- 25 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the current study is to evaluate the effect of preimplantation genetic screening (PGS) by next generation sequencing (NGS) compared to standard morphological assessment of embryos on pregnancy rates through a randomized controlled trial (RCT). All embryos will be vitrified and a single embryo transfer (SET) will be performed with either screened or unscreened embryos depending on randomization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Preimplantation Genetic Screening by NGS | The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos. |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2016-12-31
- Completion
- 2016-12-31
- First posted
- 2014-10-20
- Last updated
- 2020-05-13
- Results posted
- 2020-05-04
Locations
38 sites across 4 countries: United States, Australia, Canada, United Kingdom
Source: ClinicalTrials.gov record NCT02268786. Inclusion in this directory is not an endorsement.